One year after Philips Respironics agreed to halt manufacturing of its breathing machines in the wake of a massive recall, the medical device maker is laying off nearly 200 employees from facilities in the Pittsburgh area after decades of dominating the U.S. market.
The company, which moved part of its operations to Thailand last year, told the state Department of Labor and Industry last week that it plans to lay off about 196 workers from its centers in Murrysville, Mount Pleasant and New Kensington.
Under the company's notification, the cuts will take place between the end of this year and through June of 2026. Philips did not respond on Saturday to requests for comment.
The move marks yet another chapter in the troubled history of the once giant maker of ventilators and sleep apnea machines, which were pulled from the shelves in 2021 after tests found an industrial foam in the devices to reduce noise was capable of degrading and releasing toxic fumes into the masks of patients.
The recall prompted a Justice Department inquiry into the company's handling of the crisis, leading to an agreement last year that Philips stop selling the devices in the United States and submit to a host of other conditions.
The layoffs of employees come two years after a Post-Gazette and ProPublica investigation found the company had withheld thousands of complaints about the degrading foam for more than a decade before warning its customers — including medically vulnerable patients — about the dangers.
The company agreed in federal court to pay more than $1 billion to hundreds of people who say they were injured by the devices, which were once among the most widely sold in the world.
The Food and Drug Administration said it has received more than 560 reports of deaths associated with the devices since 2021, and the Post-Gazette has found at least 5,500 cases of cancer reported to the agency in that same period.
Though Philips has said the foam in the recalled devices did not lead to long-term harm, the material has repeatedly tested positive for genotoxicity, the ability of a chemical to cause cells to mutate, a process that can lead to cancer.
In addition to the court settlements, the company still faces a shareholders' lawsuit in federal court in the Eastern District of New York and a whistleblower complaint in federal court in Philadelphia filed by a former Philips medical director.
Hundreds of confidential documents obtained by the Post-Gazette show that nearly a dozen Philips engineers pushed the company to warn patients about the dangers of the foam before Philips removed millions of the devices from the market during the recall in 2021.
The records showed that several Philips scientists complained about the company's efforts to search for test results that would be more favorable to the company as hundreds of complaints about the defective machines poured in.
As far back as 2008, the foam in the devices failed safety tests, records show, including the lowest possible score for cytotoxicity, the ability of a chemical to destroy cells and increase the risk of organ damage.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.